Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine
Case Reports in Neurological Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crnm/4661314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Neurological Medicine, online erschienen am 06.03.2026. Verfasst von Eugenia Tsoma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine and Outpatient Care, Second Faculty of Medicine, Uzhhorod National University, Uzhhorod, Ukraine. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Karlova v Praze, Else Kröner-Fresenius-Stiftung, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Background
Mixed movement disorder due to pathogenic variants in the ADCY5 gene (MxMD‐ ADCY5 ) is a rare condition characterized predominantly by paroxysmal involuntary choreiform movements involving the limbs, face, and neck, often accompanied by dystonia and myoclonus. Speech disturbances, delayed motor development, cognitive impairment, axial hypotonia, and episodic exacerbations of dyskinesia are also common features. Currently, treatment strategies remain limited; however, several studies indicate a beneficial effect of caffeine in the management of dyskinesia.
Objective
This clinical report aims to present a case of MxMD‐ ADCY5 showing a high therapeutic response to caffeine. To our knowledge, this is the first reported Ukrainian patient with this condition demonstrating dramatic improvement in paroxysmal dyskinesia after treatment with high‐dose caffeine.
Conclusions
In our clinical observation, administration of caffeine at a total daily dose of 600 mg resulted in significant clinical improvement in an adult patient with MxMD -ADCY5 over a follow‐up period of at least 6 months. No adverse events or side effects were reported.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Family Medicine and Outpatient Care, Second Faculty of Medicine, Uzhhorod National University, Uzhhorod, Ukraine.
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, cuni.cz.
- Department of Neurology, Neurosurgery and Psychiatry, First Faculty of Medicine, Uzhhorod National University and Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod, Ukraine.
- Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany, helmholtz-muenchen.de.
- Institute of Human Genetics, Technical University of Munich, Munich, Germany, tum.de.
- Institute for Advanced Study, Technical University of Munich, Garching, Germany, tum.de.
ORCID-Profile: Eugenia Tsoma, Taras Studeniak, Robert Jech, Michael Zech, Petra Havrankova, Evžen Růžička, Lukas Kunc, Yuriy Chomolyak
Förderung
- Univerzita Karlova v Praze
- Else Kröner-Fresenius-Stiftung
- Bundesministerium für Bildung und Forschung
- Technische Universität München
Zitieren
APA
Tsoma, E., Studeniak, T., Jech, R., Zech, M., Havrankova, P., Růžička, E., Kunc, L., & Chomolyak, Y. (2026). Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine. Case Reports in Neurological Medicine, 2026(1). https://doi.org/10.1155/crnm/4661314
Vancouver
Tsoma E, Studeniak T, Jech R, Zech M, Havrankova P, Růžička E, et al. Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine. Case Reports in Neurological Medicine. 2026;2026(1). doi:10.1155/crnm/4661314
BibTeX
@article{Tsoma2026,
author = {Tsoma, Eugenia and Studeniak, Taras and Jech, Robert and Zech, Michael and Havrankova, Petra and Růžička, Evžen and Kunc, Lukas and Chomolyak, Yuriy},
title = {Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine},
journal = {Case Reports in Neurological Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crnm/4661314}
}
EUVIMED